Increased response to a 5-HT challenge after discontinuation of chronic serotonin uptake inhibition in the adult and adolescent rat brain

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Klomp, Anne ^a   Hamelink, Ralph ^a,b   Feenstra, Matthijs ^a,b   Denys, Damiaan ^a,b   Reneman, Liesbeth ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; FLUOXETINE; MONOAMINE; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN; TETRODOTOXIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; AGE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL LEVEL; CHRONIC DRUG ADMINISTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG WITHDRAWAL; IN VIVO STUDY; MALE; MEDIAL PREFRONTAL CORTEX; MEDICAL INFORMATION; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; RAT; RECEPTOR DOWN REGULATION; SEROTONIN UPTAKE; TISSUE LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; AREA UNDER THE CURVE; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; WISTAR RAT;

ANIMALS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; MALE; PREFRONTAL CORTEX; RATS, WISTAR; SEROTONIN; SEROTONIN RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 84903288806     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099873     Document Type: Article

References (55)

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617-627. (Pubitemid 40973437)
2. Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, et al. (2010) Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 49: 980-989.
3. Wijlaars LP, Nazareth I, Petersen I (2012) Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS ONE 7: e33181.
4. Andersen SL, Navalta CP (2004) Altering the course of neurodevelopment: a framework for understanding the enduring effects of psychotropic drugs. Int J Dev Neurosci 22: 423-440. (Pubitemid 39233549)
5. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, et al. (2007) Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 297: 1683-1696.
6. Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M (2007) Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev CD004851.
7. Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, et al. (2004) Efficacy and safety of antidepressants for children and adolescents. BMJ 328: 879-883. (Pubitemid 38471402)
8. March JS, Vitiello B (2009) Clinical messages from the Treatment for Adolescents With Depression Study (TADS). Am J Psychiatry 166: 1118-1123.
9. Cheung AH, Emslie GJ, Mayes TL (2005) Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 46: 735-754. JCPP1467 [pii];10.1111/j.1469-7610.2005.01467.x [doi].
10. Hazell P, O'Connell D, Heathcote D, Henry D (2000) Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev CD002317.
11. Hammad TA, Laughren T, Racoosin J (2006) Suicidality in Pediatric Patients Treated With Antidepressant Drugs. Arch Gen Psychiatry 63: 332-339. (Pubitemid 43345358)
12. Wilens TE, Biederman J, Kwon A, Chase R, Greenberg L, et al. (2003) A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 13: 143-152. (Pubitemid 37484234)
13. Wohlfarth TD, van Zwieten BJ, Lekkerkerker FJ, Gispen-de Wied CC, Ruis JR, et al. (2006) Antidepressants use in children and adolescents and the risk of suicide. Eur Neuropsychopharmacol 16: 79-83. (Pubitemid 43145812)
14. Weintrob N, Cohen D, Klipper-Aurbach Y, Zadik Z, Dickerman Z (2002) Decreased Growth During Therapy With Selective Serotonin Reuptake Inhibitors. Arch Pediatr Adolesc Med 156: 696-701. (Pubitemid 34756000)
15. Whitaker-Azmitia PM, Druse M, Walker P, Lauder JM (1996) Serotonin as a developmental signal. Behav Brain Res 73: 19-29. (Pubitemid 26008758)
16. Gaspar P, Cases O, Maroteaux L (2003) The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 4: 1002-1012. (Pubitemid 37486676)
17. Olivier JD, Blom T, Arentsen T, Homberg JR (2011) The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: A review. Prog Neuropsychopharmacol Biol Psychiatry 35: 1400-1408.
18. Klomp A, Tremoleda JL, Wylezinska M, Nederveen AJ, Feenstra M, et al. (2012) Lasting effects of chronic fluoxetine treatment on the late developing rat brain: age-dependent changes in the serotonergic neurotransmitter system assessed by pharmacological MRI. Neuroimage 59: 218-226.
19. Bouet V, Klomp A, Freret T, Wylezinska-Arridge M, Lopez-Tremoleda J, et al. (2012) Age-dependent effects of chronic fluoxetine treatment on the serotonergic system one week following treatment. Psychopharmacology (Berl) 221: 329-339.
20. Wegerer V, Moll GH, Bagli M, Rothenberger A, Ruther E, et al. (1999) Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. J Child Adolesc Psychopharmacol 9: 13-24.
21. Karanges E, Li KM, Motbey C, Callaghan PD, Katsifis A, et al. (2011) Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents? Int J Neuropsychopharmacol 14: 491-504.
22. Norrholm SD, Ouimet CC (2000) Chronic fluoxetine administration to juvenile rats prevents age-associated dendritic spine proliferation in hippocampus. Brain Res 883: 205-215.
23. Preece MA, Taylor MJ, Raley J, Blamire A, Sharp T, et al. (2009) Evidence that increased 5-HT release evokes region-specific effects on blood-oxygenation level-dependent functional magnetic resonance imaging responses in the rat brain. Neuroscience 159: 751-759.
24. Rutter JJ, Gundlah C, Auerbach SB (1994) Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett 171: 183-186. (Pubitemid 24142120)
25. Best J, Nijhout HF, Reed M (2010) Serotonin synthesis, release and reuptake in terminals: a mathematical model. Theor Biol Med Model 7: 34.
26. Sharp T (2010) Serotonergic Feedback Control. In: Müller CP, Jacobs BL, editors. Handbook of the Behavioral Neurobiology of Serotonin. London: Academic Press. 233-247.
27. Dawson LA, Nguyen HQ (2000) The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol. Neuropharmacology 39: 1044-1052. (Pubitemid 30155712)
28. de Groote L, Olivier B, Westenberg HG (2002) Extracellular serotonin in the prefrontal cortex is limited through terminal 5-HT(1B) autoreceptors: a microdialysis study in knockout mice. Psychopharmacology (Berl) 162: 419-424. (Pubitemid 35001905)
29. Descarries L, Riad M (2012) Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT. Philos Trans R Soc Lond B Biol Sci 367.
30. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, et al. (2002) Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 160: 353-361. (Pubitemid 34253277)
31. Invernizzi R, Bramante M, Samanin R (1996) Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol Biochem Behav 54: 143-147.
32. Staiti AM, Morgane PJ, Galler JR, Grivetti JY, Bass DC, et al. (2011) A microdialysis study of the medial prefrontal cortex of adolescent and adult rats. Neuropharmacology 61: 544-549.
33. Spear LP (2000) The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 24: 417-463.
34. Engelbregt MJ, Houdijk ME, Popp-Snijders C, Delemarre-van de Waal HA (2000) The effects of intra-uterine growth retardation and postnatal undernutrition on onset of puberty in male and female rats. Pediatr Res 48: 803-807.
35. Wong DT, Bymaster FP, Reid LR, Threlkeld PG (1983) Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol 32: 1287-1293. (Pubitemid 13135642)
36. Caccia S, Cappi M, Fracasso C, Garattini S (1990) Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl) 100: 509-514. (Pubitemid 20102360)
37. Beyer CE, Cremers TI (2008) Do selective serotonin reuptake inhibitors acutely increase frontal cortex levels of serotonin? Eur J Pharmacol 580: 350-354.
38. Newman ME, Shalom G, Ran A, Gur E, Van de Kar LD (2004) Chronic fluoxetine-induced desensitization of 5-HT1A and 5-HT1B autoreceptors: regional differences and effects of WAY-100635. Eur J Pharmacol 486: 25-30. (Pubitemid 38130157)
39. Raap DK, Garcia F, Muma NA, Wolf WA, Battaglia G, et al. (1999) Sustained desensitization of hypothalamic 5-Hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(Dipropylamino) Tetralin in the absence of changes in Gi/o/z proteins. J Pharmacol Exp Ther 288: 561-567. (Pubitemid 29119665)
40. Sakaue M, Somboonthum P, Nishihara B, Koyama Y, Hashimoto H, et al. (2000) Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 129: 1028-1034. (Pubitemid 30142918)
41. Perry KW, Fuller RW (1992) Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci 50: 1683-1690.
42. Amargos-Bosch M, Artigas F, Adell A (2005) Effects of acute olanzapine after sustained fluoxetine on extracellular monoamine levels in the rat medial prefrontal cortex. Eur J Pharmacol 516: 235-238. (Pubitemid 40922743)
43. Tanda G, Frau R, Di CG (1996) Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex. Psychopharmacology (Berl) 127: 83-87. (Pubitemid 26298003)
44. Alex KD, Pehek EA (2007) Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113: 296-320. (Pubitemid 46149046)
45. Gardier AM, Lepoul E, Trouvin JH, Chanut E, Dessalles MC, et al. (1994) Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: relationship with brain concentrations of fluoxetine and norfluoxetine. Life Sci 54: L51-L56.
46. Rogoz Z, Golembiowska K (2010) Effect of metyrapone on the fluoxetine-induced change in extracellular dopamine, serotonin and their metabolites in the rat frontal cortex. Pharmacol Rep 62: 1015-1022.
47. Li XM, Perry KW, Wong DT (1999) Difference in the in vivo influence of serotonin1A autoreceptors on serotonin release in prefrontal cortex and dorsal hippocampus of the same rat treated with fluoxetine. Chin J Physiol 42: 53-59. (Pubitemid 29323120)
48. Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, et al. (2006) Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry 63: 1386-1395. (Pubitemid 44878522)
49. Hervas I, Artigas F (1998) Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptors. Eur J Pharmacol 358: 9-18. (Pubitemid 28464463)
50. Lubbers LS, Zafian PT, Gautreaux C, Gordon M, Alves SE, et al. (2010) Estrogen receptor (ER) subtype agonists alter monoamine levels in the female rat brain. J Steroid Biochem Mol Biol 122: 310-317.
51. Yen TT, Fuller RW (1992) Preclinical pharmacology of fluoxetine, a serotonergic drug for weight loss. Am J Clin Nutr 55: 177S-180S.
52. Cizek LJ, Nocenti MR (1965) Relationship between water and food ingestion in the rat. Am J Physiol 208: 615-620.
53. Strominger JL (1947) The relation between water intake and food intake in normal rats and in rats with hypothalamic hyperphasia. Yale J Biol Med 19: 279-288.
54. Caballero J, Nahata MC (2005) Selective serotonin-reuptake inhibitors and suicidal ideation and behavior in children. Am J Health Syst Pharm 62: 864-867. (Pubitemid 40547372)
55. DeVane CL (1999) Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 19: 443-466.